Risk factors
Acadia Pharmaceuticals (ACAD) risk factors
Item 1A of every Acadia Pharmaceuticals Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors63 risks3 new7 dropped16 reworded
Acadia highlights international expansion risks for trofinetide, global supply chain dependencies including China, and updated corporate tax legislation.
Filed Feb 26, 2026 - FY2024 10-K risk factors67 risks
Acacia depends heavily on commercializing NUPLAZID and DAYBUE and obtaining approvals for trofinetide in the EU and outside North America. The company faces high clinical trial failure risks, heavy reliance on third-party manufacturers like Patheon, and accumulated net losses of approximately $2.2 billion.
Filed Feb 27, 2025